超声内镜引导下经针微型活检钳活检对胰腺囊性病变分型的疗效与安全性
本研究回顾性分析45例胰腺囊性病变患者,评估EUS-TTNB的技术成功率、诊断率及不良事件。技术成功100%,诊断率82%,10例改变了分型诊断;7%发生不良事件,无危及生命事件。
要点
- EUS-TTNB技术成功率高,诊断率达82%,可改变部分患者的胰腺囊性病变分型。
- 不良事件发生率7%,包括急性胰腺炎和囊内出血,无危及生命事件。
核心结论
- EUS-TTNB对胰腺囊性病变分型具有高技术可行性、高诊断率和良好安全性,可能改善分型诊断。
研究设计与样本
- 回顾性分析前瞻性收集的Asan Medical Center EUS-TTNB数据库,纳入2019年1月至2021年1月间接受EUS-TTNB的胰腺囊性病变患者45例。
主要发现
- EUS-TTNB技术成功率为100%(45/45),组织学诊断率为82%(37/45)。
- 与 presumptive 诊断相比,EUS-TTNB在10例患者中改变了胰腺囊性病变分型。
- 随访期间3例(7%)发生不良事件:2例急性胰腺炎,1例囊内出血,无危及生命事件。
临床怎么用
- EUS-TTNB可用于胰腺囊性病变的分型诊断,操作时宜争取每次获取≥4条可见活检标本以提高诊断率。
局限性
- 本研究为单中心回顾性分析,样本量有限(45例),且缺乏标准化操作方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: EUS-guided through-the-needle biopsy sampling (EUS-TTNB) using microbiopsy forceps is performed for the accurate diagnosis of pancreatic cystic lesions (PCLs). However, there are no standardized protocols for this procedure, and the amount of data on its efficacy is limited. Here, we evaluated the feasibility, efficacy, and safety of EUS-TTNB in categorizing the types of PCLs and identified the factors associated with diagnostic failure. METHODS: The prospectively collected and maintained EUS-TTNB database at Asan Medical Center was reviewed to identify patients with PCLs who underwent EUS-TTNB between January 2019 and January 2021. The primary outcomes were technical success, diagnostic yield, and adverse events. Factors contributing to diagnostic failure and the discrepancies in the diagnosis made by conventional modalities (ie, EUS morphology, cross-sectional imaging, and cystic fluid analysis) were also evaluated. RESULTS: Forty-five patients were analyzed. EUS-TTNB was successfully performed in all patients (technical success, 100%). Histologic diagnosis of PCLs was made in 37 patients (diagnostic yield, 82%). When comparing EUS-TTNB with a presumptive diagnosis, EUS-TTNB changed the diagnosis in 10 patients in terms of the categorization of the types of PCLs. The diagnostic yield was significantly higher in those who had 4 or more visible biopsy specimens per session (93%) than in those with fewer than 4 visible biopsy specimens per session (67%; P = .045). During follow-up, 3 patients (7%) experienced adverse events (2 acute pancreatitis, 1 intracystic bleeding), and no life-threatening adverse event occurred. CONCLUSIONS: EUS-TTNB showed high technical feasibility, diagnostic yield, and good safety profile. EUS-TTNB may improve the categorization of the types of PCLs. Studies with standardized procedure protocols are needed to reduce the diagnostic failure for the types of PCLs.
引用
- Cho SH, Song TJ, Seo DW, et al. Efficacy and safety of EUS-guided through-the-needle microforceps biopsy sampling in categorizing the type of pancreatic cystic lesions. Gastrointest Endosc. 2021. PMID: 34624305. doi:10.1016/j.gie.2021.09.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。